Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Bangsgaard, Nannie ^a   Houtkamp, Mischa ^b   Schuurhuis, Danita H ^b   Parren, Paul W H I ^b   Baadsgaard, Ole ^c   Niessen, Hans W M ^d   Skov, Lone ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GENMAB   (Netherlands)

^c Genmab   (Denmark)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY 10F8; INTERLEUKIN 8; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; HAIR FOLLICLE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INFLAMMATORY CELL; INJECTION SITE; MALE; NEUTROPHIL; NORMAL HUMAN; PAPULOPUSTULAR RASH; PUSTULE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SKIN BIOPSY; SKIN INFLAMMATION;

ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-8; NEUTRALIZATION TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN DISEASES;

EID: 84862648351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039706     Document Type: Article

References (44)

1. Hansen LA, Woodson RL, 2nd, Holbus S, Strain K, Lo YC, et al (2000) The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. Cancer Res 60: 3328-3332.
2. Mimeault M, Bonenfant D, Batra SK, (2004) New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers. Skin Pharmacol Physiol 17: 153-166.
3. Rowinsky EK, (2004) The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 55: 433-457.
4. Vivanco I, Mellinghoff IK, (2010) Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 22: 573-578.
5. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, et al. (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55: 657-670.
6. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW, (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56: 317-326.
7. Lacouture ME, (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6: 803-812.
8. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, et al. (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6: 491-500.
9. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794.
10. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, et al. (2011) Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study. Invest New Drugs 29: 680-687.
11. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
12. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208.
13. Alexandrescu DT, Vaillant JG, Dasanu CA, (2007) Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 32: 71-74.
14. Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, et al. (2011) Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 16: 228-238.
15. Segaert S, Van Cutsem E, (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16: 1425-1433.
16. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, et al. (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144: 1169-1176.
17. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, et al. (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151: 238-241.
18. Kimyai-Asadi A, Jih MH, (2002) Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 138: 129-131.
19. Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, et al. (2008) IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol 181: 669-679.
20. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, et al. (2004) Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173: 4699-4707.
21. Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, et al. (2011) Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12: 333-343.
22. Journagan S, Obadiah J, (2006) An acneiform eruption due to erlotinib: prognostic implications and management. J Am Acad Dermatol 54: 358-360.
23. Molinari E, De Quatrebarbes J, Andre T, Aractingi S, (2005) Cetuximab-induced acne. Dermatology 211: 330-333.
24. Gusterson B, Cowley G, Smith JA, Ozanne B, (1984) Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 8: 649-658.
25. Nanney LB, Stoscheck CM, King LE Jr, Underwood RA, Holbrook KA, (1990) Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 94: 742-748.
26. Jost M, Kari C, Rodeck U, (2000) The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 10: 505-510.
27. Nanney LB, Magid M, Stoscheck CM, King LE Jr, (1984) Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 83: 385-393.
28. Pastore S, Mascia F, Mariotti F, Dattilo C, Mariani V, et al. (2005) ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol 174: 5047-5056.
29. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, et al. (1997) EGF-R dependent regulation of keratinocyte survival. J Cell Sci 110 (Pt 2): 113-121.
30. Sibilia M, Wagner EF, (1995) Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269: 234-238.
31. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, et al. (1995) Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269: 230-234.
32. Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang HZ, et al. (1994) Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 12: 730-739.
33. Mascia F, Mariani V, Girolomoni G, Pastore S, (2003) Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163: 303-312.
34. Busam Kea, (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. British Journal of Dermatology 144: 1169-1176.
35. Surguladze D, Deevi D, Claros N, Corcoran E, Wang S, et al. (2009) Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res 69: 5643-5647.
36. Han SS, Lee M, Park GH, Bang SH, Kang YK, et al. (2010) Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br J Dermatol 162: 371-379.
37. Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K, (1989) Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor. Immunology 68: 31-36.
38. Takematsu H, Isono N, Kato T, Tagami H, (1990) Normal human epidermal keratinocyte-derived neutrophil chemotactic factor. Tohoku J Exp Med 162: 1-13.
39. Hoffmann TK, Schirlau K, Sonkoly E, Brandau S, Lang S, et al. (2009) A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer 124: 2589-2596.
40. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K, (1989) The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243: 1464-1466.
41. Schroder JM, Mrowietz U, Morita E, Christophers E, (1987) Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol 139: 3474-3483.
42. Pastore S, Mascia F, Mariani V, Girolomoni G, (2008) The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 128: 1365-1374.
43. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, et al. (1996) Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97: 2792-2802.
44. Salcedo R, Martins-Green M, Gertz B, Oppenheim JJ, Murphy WJ, (2002) Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts. Clinical Cancer Research 8: 2655-2665.